Research Areas of Focus

Cure Alzheimer’s Fund set a record for scientific funding in 2024. We deployed $30 million for research purposes, an 8% increase from the previous record set in 2023 ($27.8 million). This total represents funds in support of 120 grants and 137 named investigators.

Alzheimer’s disease (AD) community is to provide funding where other entities will not, and prioritize returns measured in scientific progress, not potential profits. Thus, Cure Alzheimer’s Fund continues to prioritize target identification for Alzheimer’s science research over proprietary drug development, with most distributions in 2024—92% of awards—directed to early-stage research.

Most funding went to translational research projects and a large fraction—approximately 24%—of all funded studies are on the neurodegenerative pathways in Alzheimer’s disease. Under the right circumstances, CureAlz will continue to fund a great idea as it moves downstream closer to the clinic and patients; drug development efforts in this vein represent approximately 6% of funding in 2024. We funded a healthy balance of renewing projects and entirely new or follow-on projects as part of our portfolio.

The evident progress and promising discoveries enabled by this funding are more important than these numbers. The incredible successes our researchers have had in publishing their impactful work is a sign that we are making the right funding decisions to help patients and their families who desperately need solutions.